Selzer, Paul M. (ed.) Antiparasitic and Antibacterial Drug Discovery From Molecular Targets to Drug Candidates Drug Discovery in Infectious Diseases (Volume 1)
1. Edition - April 2009 155.- Euro 2009. XX, 489 Pages, Hardcover 110 Fig. (42 Colored Fig.), 28 Tab. - Handbook/Reference Book - ISBN-10: 3-527-32327-9 ISBN-13: 978-3-527-32327-2 - Wiley-VCH, Weinheim
Short description Mainly addressing parasitic diseases but also those caused by bacteria, this much-needed reference provides a unique insight into commercial science's approach to infectious diseases. The authors have first-hand experience of drug discovery units in the pharmaceutical industry.
From the contents Preamble Editor Preface PART I Drug Discovery Approaches 1 Target identification and mechanism-based screening for anthelmintics: Application of veterinary antiparasitic research programmes to search for new antiparasitic drugs for human indications 2 Anthelmintic resistance as a guide to the discovery of new drugs? 3 Drug discovery for neglected diseases: view of a public-private partnership 4 Bioinformatics and Chemoinformatics: Key Technologies in the Drug Discovery Process 5 Target identification and validation in anti parasitic drug discovery 6 Selective Drug Targets in Parasites 7 Lessons Learned From Target Based Lead Discovery 8 Approaches towards Antiparasitic Drug Candidates for Veterinary Use 9 Learning to Relate Structural Space with Property Space 10 Recruiting the Host Defense Mechanisms: Roles for Vaccines and Chemotherapeutics PART II Protozoan Parasites 11 Proteases of Parasitic Protozoa - Current Status and Validation 12 In Search of Trypanocidal Drugs 13 Trypanosomatid protein kinases as potential drug targets 14 Targeting the malaria kinome; discovering kinase inhibitors as novel antimalarial agents 15 Malaria and anti-malarials - a focused view PART III Multicellular Parasites 16 Chemotherapeutic development strategies for schistosomiasis 17 Searching new Anti-Parasitics in the Virtual Space 18 Cyclooctadepsipeptides - an anthelmintically active class of compounds exhibiting a novel mode of action 19 Chemical Optimization of Anthelmintic Compounds - a Case Study PART IV Bacteria 20 Pathogenomics: identification of novel drug targets and vaccine candidates in bacteria 21 Tuberculosis Drug Discovery: Issues, Gaps and the Way Forward 22 Decreasing the number of gaps in the draft assembly of the Mannheimia haemolytica M7/2 genome sequence 23 Total synthesis and configurational assignment of pasteurestin A and B, a natural product with antimicrobial acitivty on Pasteurellaceae
